Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 90

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 3
Chunk 90
---
of leadership changes, the continued shutdown, staff reductions or otherwise, at the FDA, other government agencies or comparable foreign
regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. Changes and cuts in FDA staffing also could result in delays in the FDA’s responsiveness
or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements
in a timely fashion or at all. There is also substantial uncertainty as to how regulatory reform measures being implemented by the current
U.S. administration, and other political developments, such as the continued government shutdowns or work stoppages, would impact other
U.S. regulatory agencies, such as the FDA, SEC and U.S. Patent and Trademark Office (USPTO), on which our operations rely. For example,
the U.S. government has shut down as of October 1, 2025 and certain regulatory agencies, such as the FDA and the SEC, have had to furlough
critical employees and stop critical activities. If a prolonged government shutdown occurs, including as a result of reaching the debt
ceiling or staffing changes, it could significantly impact the ability of the FDA and USPTO to timely review and process our regulatory
submissions, which could have a material adverse effect on our business. Further, the continued government shutdown could impact our ability
to access the public markets and obtain additional capital in the future in order to properly capitalize and continue our operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS.

We did not issue or sell any unregistered securities during the three
months ended September 30, 2025.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

Rule 10b5-1 Trading Plans 

During the three months ended September 30, 2025,
none of our directors or officers entered into, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” that were intended to satisfy the affirmative defense conditions of Rule 10b5-1, in each case as defined
in Item 408 of Regulation S-K.

 25 

ITEM 6. EXHIBITS.

(a) Exhibits